21 January 2013
A radical new implant could transform the way women suffering from cancer are treated.
Ovarian Cancer Action revealed that a cancer sufferer was implanted with a new device that "manages" malignant ascites, which is a dangerous fluid that builds up in the abdomen.
The battery-operated apparatus, known as the alfapump system, is implanted under the skin of a person and helps to draw fluid away from the abdomen and into the bladder.
This is important as the fluid is then discharged with the passing of urine, where at present patients have to visit hospital to have the fluid drained.
"The alfapump has the potential to provide an exciting opportunity to monitor ovarian cancer patients more closely and tailor our care to individual patients," said professor Hani Gabra, director of Ovarian Cancer Action Research Centre.
"My hope is that this will be a major breakthrough in our approach to the treatment of ovarian cancer."
Gilda Witte, chief executive of Ovarian Cancer Action, added that the device has the potential to boost the quality of life with women suffering from ovarian cancer.
"We’re delighted that we’re able to facilitate use of the alfapump system at the Ovarian Cancer Action Research Centre," she concluded.
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.